Wanling Xie1, Ming Yang2, June Chan3, Tong Sun2, Lorelei A Mucci4,5, Kathryn L Penney4,5, Gwo-Shu Mary Lee2, Philip W Kantoff2. 1. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 3. Department of Epidemiology and Biostatistics and Urology, University of California, San Francisco, California. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 5. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Genetic variations in some of the selenoprotein genes, alone or together with an individual's selenium status, may influence risk or progression of prostate cancer. We investigated the impact of genetic variants of selenoproteins on plasma selenium levels and cancer aggressiveness at diagnosis in men with localized prostate cancer (PCa). METHODS: The study cohort comprised 722 patients seen at Dana-Farber Cancer Institute who had localized/locally advanced PCa (i.e., stage T3 or less, N0, and M0) from 1994 to 2001. Fifty-five tagging single nucleotide polymorphisms (SNPs) from six selenoprotein genes (TXNRD1, TXNRD2, SEP15, GPX3, SELENBP1, and SEPP1) were analyzed. Logistic regression is used to examine associations of genotypes and plasma selenium levels with risk of aggressive disease, defined as D'Amico intermediate/high risk categories. Step down permutation was applied to adjust for multiple comparisons. RESULTS: Three hundred and forty-eight patients (48%) had aggressive disease at diagnosis. Two SNPs were associated with cancer aggressiveness at diagnosis (unadjusted P = 0.017 and 0.018, respectively). The odds ratio for aggressive disease in patients carrying TXNRD2 rs1005873-AG/GG genotypes or SELENBP1 rs10788804-AG/AA genotypes was 1.54 (95% CI = 1.08, 2.20) and 1.45 (95% CI = 1.07, 1.98), respectively, compared to TXNRD2 rs1005873-AA or SELENBP1 rs10788804-GG carriers. Four SNPs in TXNRD2 (rs1005873, rs13054371, rs3788310, and rs9606174) and the rs230820 in SEPP1 were associated with plasma selenium levels (unadjusted P < 0.05). Permutation adjusted P-values were not statistically significant for all these comparisons at the cut-off point of 0.05. CONCLUSION: We identified polymorphisms in selenoproteins that may influence the plasma selenium levels and may be associated with the risk of presenting with aggressive PCa in men with localized or locally advanced PCa. These results should be validated in other independent datasets.
BACKGROUND: Genetic variations in some of the selenoprotein genes, alone or together with an individual's selenium status, may influence risk or progression of prostate cancer. We investigated the impact of genetic variants of selenoproteins on plasma selenium levels and cancer aggressiveness at diagnosis in men with localized prostate cancer (PCa). METHODS: The study cohort comprised 722 patients seen at Dana-Farber Cancer Institute who had localized/locally advanced PCa (i.e., stage T3 or less, N0, and M0) from 1994 to 2001. Fifty-five tagging single nucleotide polymorphisms (SNPs) from six selenoprotein genes (TXNRD1, TXNRD2, SEP15, GPX3, SELENBP1, and SEPP1) were analyzed. Logistic regression is used to examine associations of genotypes and plasma selenium levels with risk of aggressive disease, defined as D'Amico intermediate/high risk categories. Step down permutation was applied to adjust for multiple comparisons. RESULTS: Three hundred and forty-eight patients (48%) had aggressive disease at diagnosis. Two SNPs were associated with cancer aggressiveness at diagnosis (unadjusted P = 0.017 and 0.018, respectively). The odds ratio for aggressive disease in patients carrying TXNRD2rs1005873-AG/GG genotypes or SELENBP1rs10788804-AG/AA genotypes was 1.54 (95% CI = 1.08, 2.20) and 1.45 (95% CI = 1.07, 1.98), respectively, compared to TXNRD2rs1005873-AA or SELENBP1rs10788804-GG carriers. Four SNPs in TXNRD2 (rs1005873, rs13054371, rs3788310, and rs9606174) and the rs230820 in SEPP1 were associated with plasma selenium levels (unadjusted P < 0.05). Permutation adjusted P-values were not statistically significant for all these comparisons at the cut-off point of 0.05. CONCLUSION: We identified polymorphisms in selenoproteins that may influence the plasma selenium levels and may be associated with the risk of presenting with aggressive PCa in men with localized or locally advanced PCa. These results should be validated in other independent datasets.
Authors: Amy L Silvers; Lin Lin; Adam J Bass; Guoan Chen; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Thomas J Giordano; Mark B Orringer; David G Beer; Andrew C Chang Journal: Clin Cancer Res Date: 2010-03-23 Impact factor: 12.531
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: Miyako Abe; Wanling Xie; Meredith M Regan; Irena B King; Meir J Stampfer; Philip W Kantoff; William K Oh; June M Chan Journal: BJU Int Date: 2011-01 Impact factor: 5.588
Authors: E Kumaraswamy; A Malykh; K V Korotkov; S Kozyavkin; Y Hu; S Y Kwon; M E Moustafa; B A Carlson; M J Berry; B J Lee; D L Hatfield; A M Diamond; V N Gladyshev Journal: J Biol Chem Date: 2000-11-10 Impact factor: 5.157
Authors: K Yoshizawa; W C Willett; S J Morris; M J Stampfer; D Spiegelman; E B Rimm; E Giovannucci Journal: J Natl Cancer Inst Date: 1998-08-19 Impact factor: 13.506
Authors: Haojie Li; Meir J Stampfer; Edward L Giovannucci; J Steven Morris; Walter C Willett; J Michael Gaziano; Jing Ma Journal: J Natl Cancer Inst Date: 2004-05-05 Impact factor: 13.506
Authors: John P Gerstenberger; Scott R Bauer; Erin L Van Blarigan; Eduardo Sosa; Xiaoling Song; John S Witte; Peter R Carroll; June M Chan Journal: Prostate Date: 2014-10-04 Impact factor: 4.104
Authors: Yan-Mei Ma; Yong-Zhen Guo; Gordon Ibeanu; Li-Yao Wang; Jian-Da Dong; Juan Wang; Li Jing; Jian-Zhong Zhang; P Andy Li Journal: Int J Biol Sci Date: 2017-11-01 Impact factor: 6.580